
    
      Objective of the study:

      Does melatonin by improving sleep parameters improve quality of life of hemodialysis
      patients?

      Study design:

      Placebo-controlled, double-blind, randomized trial

      Study population:

      hemodialysis patients

      Intervention:

      melatonin 3 mg once daily (or placebo)

      Primary study parameters/outcome of the study:

        1. improvement of vitality (dimension quality of life) by 15 points (RAND SF 36)

        2. improvement general health by 15 points (dimension quality of life, RAND SF 36)

      Secondary study parameters/outcome of the study:

        1. Change in biochemical parameters

        2. Change in ProBNP

        3. Change in nutritional status

        4. Change in use of medication

        5. Change in preload
    
  